Exelixis Q2 FY26 GAAP net income rises 14.72% to $212.1 million; revenue increases 10.63% to $628.7 million

Reuters2026/08/05 20:56

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Exelixis posted Q2 2026 revenue of $628.7 million, up 10.63% from a year earlier, driven by higher sales volume.
GAAP net income rose to $212.1 million, while GAAP diluted EPS increased to $0.82.
R&D expense climbed to $212 million; SG&A expense increased to $147.6 million on higher marketing activity.
Updated 2026 revenue outlook fell to $2.5 billion-$2.55 billion; R&D expense forecast narrowed to $825 million-$875 million.
Management highlighted continued cabozantinib growth, preparations for a potential zanzalintinib launch in metastatic CRC, with an FDA action date of Dec. 3, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Exelixis Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260804452015) on August 05, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Exelixis Q2 FY26 GAAP net income rises 14.72% to $212.1 million; revenue increases 10.63% to $628.7 million

You may also like

Crypto prices